OKLAHOMA CITY Dec. 19 2011 PRNewswire Selexys Pharmaceuticals announced today that it has completed a Phase I clinical study of its lead compound SelG1 an antibody specific for the proinflammatory cell adhesion molecule Pselectin.&160; The placeboc...
↧